摘要
癌泰德(cantide)是目前正在开发中的针对端粒酶(hTERT)的新型反义核酸药物。临床前研究表明,它能够选择性地抑制肿瘤活性并延长实验动物的生存期,通过抑制hTERT基因的表达来减少hTERT的活性,并能通过诱导Caspase依赖的凋亡起到快速的抑癌作用。现综述其毒理学和药动学的研究情况,包括体内和体外药效学、抗癌机制、急性毒性试验及药动学等。以上研究结果表明,癌泰德在体内和体外均安全和有效。
Cantide is an emerging hTERT-targeted antisense oligodeoxynucleotide. Pre-clinical data indicated that it selectively inhibits tumor growth and prolongs the life expectancy of carcinous animals. Cantide decreases telomerase activity by inhibiting the expression of hTERT gene and shows a rapid anti-tumor effect by inducing the Caspase-dependent apoptosis. This review presents the mechanism, toxicology, pharmacodynamics and pharmacokinetics of this effective and safe antisense oligonucleotide as well as the potential for the development of human therapy against carcinomas.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2006年第19期1615-1619,共5页
Chinese Journal of New Drugs
基金
国家重大基金专项(2002AA2Z3337)
关键词
端粒酶
癌泰德
药效
毒理
药动学
human telomerase reverse transcriptase (hTERT)
cantide
pharmacodynamics
toxicity
pharmacokinetics